CN113784953A - 可用于治疗高血糖症的杂环基(苯基)甲醇化合物 - Google Patents

可用于治疗高血糖症的杂环基(苯基)甲醇化合物 Download PDF

Info

Publication number
CN113784953A
CN113784953A CN202080032751.5A CN202080032751A CN113784953A CN 113784953 A CN113784953 A CN 113784953A CN 202080032751 A CN202080032751 A CN 202080032751A CN 113784953 A CN113784953 A CN 113784953A
Authority
CN
China
Prior art keywords
methanol
dimethylpyrrolidin
compound
hyperglycemia
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080032751.5A
Other languages
English (en)
Chinese (zh)
Inventor
B·佩尔卡曼
T·本特松
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atoki
Original Assignee
Atoki
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atoki filed Critical Atoki
Publication of CN113784953A publication Critical patent/CN113784953A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/54—Spiro-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080032751.5A 2019-03-20 2020-03-20 可用于治疗高血糖症的杂环基(苯基)甲醇化合物 Pending CN113784953A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1903827.2 2019-03-20
GBGB1903827.2A GB201903827D0 (en) 2019-03-20 2019-03-20 New compounds and methods
PCT/GB2020/050762 WO2020188301A1 (en) 2019-03-20 2020-03-20 Heterocyclyl(phenyl)methanol compounds useful in the treatment of hyperglycaemia

Publications (1)

Publication Number Publication Date
CN113784953A true CN113784953A (zh) 2021-12-10

Family

ID=66381053

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080032751.5A Pending CN113784953A (zh) 2019-03-20 2020-03-20 可用于治疗高血糖症的杂环基(苯基)甲醇化合物

Country Status (13)

Country Link
US (1) US20220152004A1 (enExample)
EP (1) EP3941468A1 (enExample)
JP (1) JP2022525795A (enExample)
KR (1) KR20210141622A (enExample)
CN (1) CN113784953A (enExample)
AU (1) AU2020243426A1 (enExample)
BR (1) BR112021018578A2 (enExample)
CA (1) CA3133768A1 (enExample)
GB (1) GB201903827D0 (enExample)
IL (1) IL286432A (enExample)
MX (1) MX2021011286A (enExample)
TW (1) TWI846843B (enExample)
WO (1) WO2020188301A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714740D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714736D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714745D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201903832D0 (en) 2019-03-20 2019-05-01 Atrogi Ab New compounds and methods
GB202204085D0 (en) * 2022-03-23 2022-05-04 Atrogi Ab New compounds and methods

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3985887A (en) * 1973-10-19 1976-10-12 Smithkline Corporation 3-Substituted-4-hydroxyphenyl-2-piperidylcarbinols as β-adrenergic stimulants
EP0128120A2 (de) * 1983-06-02 1984-12-12 Ciba-Geigy Ag Trisubstituierte Oxazolidinone
CN1302184A (zh) * 1998-06-18 2001-07-04 诺瓦提斯公司 防治害虫的组合物
CN1305344A (zh) * 1998-06-18 2001-07-25 诺瓦提斯公司 驱避与防止害虫的组合物
CN101043881A (zh) * 2004-09-07 2007-09-26 索塞R&D有限公司 炎症疾病和疼痛的治疗
JP2010530402A (ja) * 2007-06-21 2010-09-09 サノフイ−アベンテイス 置換インダゾール類、それらの調製および治療におけるその使用
CN111164072A (zh) * 2017-09-13 2020-05-15 阿托基公司 β-羟基杂环胺及其在治疗高糖血症中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3910933A (en) * 1973-10-19 1975-10-07 Smithkline Corp 3-Substituted-4-hydroxyphenyl-2-piperidylcarbinols
NO753594L (enExample) * 1974-10-30 1976-05-03 Scherico Ltd
FR2436779A1 (fr) * 1978-09-22 1980-04-18 Pharmindustrie Derives de pyrrolidine-2 methanol utilisables comme medicaments
FR2460929A1 (fr) * 1979-07-06 1981-01-30 Roussel Uclaf Nouveaux derives de l'a-phenyl 2-pyrrolidinemethanol et leur sels, procede de preparation, application a titre de medicaments et compositions les renfermant
WO2006027579A2 (en) * 2004-09-07 2006-03-16 Sosei R & D Ltd. The treatment of inflammatory disorders and pain
GB2435979A (en) * 2006-03-07 2007-09-12 Helen Theresa Haywood Door intercom telephone device

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3985887A (en) * 1973-10-19 1976-10-12 Smithkline Corporation 3-Substituted-4-hydroxyphenyl-2-piperidylcarbinols as β-adrenergic stimulants
EP0128120A2 (de) * 1983-06-02 1984-12-12 Ciba-Geigy Ag Trisubstituierte Oxazolidinone
CN1302184A (zh) * 1998-06-18 2001-07-04 诺瓦提斯公司 防治害虫的组合物
CN1305344A (zh) * 1998-06-18 2001-07-25 诺瓦提斯公司 驱避与防止害虫的组合物
CN101043881A (zh) * 2004-09-07 2007-09-26 索塞R&D有限公司 炎症疾病和疼痛的治疗
JP2010530402A (ja) * 2007-06-21 2010-09-09 サノフイ−アベンテイス 置換インダゾール類、それらの調製および治療におけるその使用
CN111164072A (zh) * 2017-09-13 2020-05-15 阿托基公司 β-羟基杂环胺及其在治疗高糖血症中的用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEN-XI YE等: "Dual catalysis for enantioselective convergent synthesis of enantiopure vicinal amino alcohols", 《NATURE COMMUNICATIONS》, vol. 9, no. 1, 31 December 2018 (2018-12-31), pages 4, XP002800110, DOI: 10.1038/s41467-017-02698-4 *

Also Published As

Publication number Publication date
US20220152004A1 (en) 2022-05-19
KR20210141622A (ko) 2021-11-23
EP3941468A1 (en) 2022-01-26
CA3133768A1 (en) 2020-09-24
MX2021011286A (es) 2022-01-24
IL286432A (en) 2021-10-31
GB201903827D0 (en) 2019-05-01
TW202102473A (zh) 2021-01-16
TWI846843B (zh) 2024-07-01
JP2022525795A (ja) 2022-05-19
AU2020243426A1 (en) 2021-11-04
WO2020188301A1 (en) 2020-09-24
BR112021018578A2 (pt) 2021-11-23

Similar Documents

Publication Publication Date Title
TWI846843B (zh) 適用於治療高血糖症的雜環基(苯基)甲醇化合物
EP3681872B1 (en) Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia
JP7346388B2 (ja) ベータ－ヒドロキシ複素環アミンおよび高血糖症の治療におけるそれらの使用
CN111148731B (zh) 氟苯基β-羟乙胺及其在治疗高糖血症中的用途
CN113784961A (zh) 可用于治疗高血糖症的杂芳基(杂环基)甲醇化合物
US11793774B2 (en) Chiral beta-hydroxyethylamines and their use in the treatment of hyperglycemia
TW202220956A (zh) 新穎芳基氮雜雙環［２．１．１］己基甲醇及其醫藥用途
TW202438055A (zh) 用於處置高血糖及高血糖為特徵的疾患之取代羥甲基吡咯啶類
HK40033371A (en) Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia
HK40033371B (en) Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20211210